Wall Street brokerages expect BioScrip Inc (NASDAQ:BIOS) to announce earnings of ($0.10) per share for the current quarter, Zacks reports. Two analysts have made estimates for BioScrip’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.12). BioScrip reported earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The business is scheduled to report its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.23). For the next financial year, analysts forecast that the company will post earnings of ($0.16) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover BioScrip.
BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $178.96 million for the quarter, compared to analysts’ expectations of $179.23 million. During the same quarter in the prior year, the business posted ($0.12) EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis.
BIOS traded down $0.11 on Friday, hitting $2.78. The company had a trading volume of 532,056 shares, compared to its average volume of 1,177,508. The company has a fifty day simple moving average of $2.36. BioScrip has a 12-month low of $1.56 and a 12-month high of $4.14. The stock has a market cap of $369.54 million, a PE ratio of -5.67 and a beta of 0.68.
Several large investors have recently added to or reduced their stakes in the stock. Maven Securities LTD bought a new position in shares of BioScrip during the fourth quarter valued at approximately $45,000. Caxton Associates LP acquired a new stake in BioScrip in the fourth quarter worth approximately $52,000. SG Americas Securities LLC acquired a new stake in BioScrip in the first quarter worth approximately $49,000. FNY Investment Advisers LLC lifted its position in BioScrip by 840.9% in the first quarter. FNY Investment Advisers LLC now owns 25,000 shares of the company’s stock worth $50,000 after purchasing an additional 22,343 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its position in BioScrip by 205.2% in the first quarter. BNP Paribas Arbitrage SA now owns 26,338 shares of the company’s stock worth $53,000 after purchasing an additional 17,709 shares during the period. Institutional investors and hedge funds own 78.60% of the company’s stock.
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Recommended Story: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.